Nov 20 (Reuters) - Kura Oncology ( KURA ) said on
Wednesday it will collaborate with Japan's Kyowa Kirin ( KYKOF )
to develop and commercialize the blood cancer therapy
ziftomenib.
Kura said it will receive an upfront payment of $330 million
and up to $1.2 billion in total milestone payments as part of
the deal.